20 results about "Tumor Weight" patented technology

The application discloses a pancreatic cancer immunotherapy drug composition for jointly targeting CD96 and PD-1, relates to the technical field of biological medicine, and comprises an anti-human CD96 blocking antibody and an anti-human PD-1 blocking antibody. By jointly blocking the double immune checkpoints of CD96 and PD-1, the pancreatic cancer immunotherapy drug composition presents a significant synergistic effect compared with single antibody treatment, can effectively enhance the killing activity of T cells on pancreatic cancer cells, reverses the immune suppression microenvironment of pancreatic cancer, and restores the anti-tumor immune response of the body. The in-vivo experimental results show that the drug composition can significantly inhibit the growth of transplanted tumors, reduce the tumor volume and the tumor weight, and the tumor inhibition effect is obviously better than that of a single drug group. The preparation has stable properties and simple administration, and provides a safe and effective new immunotherapy scheme with a conversion application prospect for clinically refractory pancreatic cancer.

The invention belongs to the field of medicines, and relates to a novel application of a Chinese knotweed rhizome and aloe bowel-relaxing capsule, in particular to a novel application of the Chinese knotweed rhizome and aloe bowel-relaxing capsule in a medicine for treating colorectal cancer. The colorectal cancer model mice are administered with the Chinese knotweed rhizome-aloe bowel-relaxing capsules, the difference of indexes of each group of mice is observed, and the prevention and treatment effect of the Chinese knotweed rhizome-aloe bowel-relaxing capsules on colorectal cancer is investigated. Experimental results show that the Chinese knotweed rhizome and aloe bowel-relaxing capsule not only can obviously improve the body mass of a mouse with colorectal cancer and reduce the number of tumors of the mouse with colorectal cancer, but also can reduce the tumor weight of the mouse with colorectal cancer, and is remarkable in tumor inhibition effect. The Chinese knotweed rhizome and aloe bowel-relaxing capsule is used for treating colorectal cancer, can avoid toxic and side effects of western medicines, and is higher in safety.

The application provides application of idebenone in preparation of a medicine for treating osteosarcoma. The application of idebenone or a pharmaceutically acceptable salt thereof in preparation of the medicine for treating osteosarcoma is achieved by carrying out proliferation experiments (CCK8 method) and invasion experiments (transwell invasion experiment) of osteosarcoma cell lines in vitro, quantitative analysis of cell viability in the CCK8 method proliferation experiment and quantitative analysis of the number of penetrated cells in the transwell invasion experiment; and constructing a nude mouse CDX (cell-derived xenograft) model, a PDX (human-derived xenograft) model and a tibial orthotopic / metastatic tumor model, intraperitoneally injecting idebenone, and quantitatively analyzing the tumor volume and tumor weight in the CDX model, the tumor volume and tumor weight in the PDX model and the tumor volume, the weight of the affected limb and the number of lung metastases in the tibial orthotopic / metastatic tumor model, which fully indicates that idebenone can inhibit the proliferation, invasion and metastasis of osteosarcoma.

The invention discloses application of albiflorin in preparation of medicines for adjuvant therapy of cancers, and particularly relates to application of albiflorin in treatment of cancer-related fatigue and tumor-related depression. A chemotherapy-induced CRF blood deficiency and liver depression syndrome mouse model is adopted, the treatment effect of albiflorin on CRF and CRD is investigated through the tumor weight, the inhibition rate, behavioral indexes and peripheral hemogram, and the effect is better than that of a radix paeoniae alba water extract.

The invention discloses a composition for treating brain glioma and application thereof, and relates to the technical field of biological medicine. The composition for treating the brain glioma is prepared from temozolomide and tetrathiomolybdate. According to the application disclosed by the invention, by analyzing the inhibition condition of temozolomide and tetrathiomolybdate on glioma cells under the conditions of independent medication and combined medication and quantitatively calculating the combined inhibition effect, a result shows that temozolomide and tetrathiomolybdate have a synergistic treatment effect in a glioma cell line. In a nude mouse subcutaneous tumor implantation model, temozolomide and tetrathiomolybdate are combined for treatment, the tumor weight and the animal survival condition are detected, the combined inhibition effect is quantitatively calculated, the side effect of the medicine is detected, and the result shows that temozolomide and tetrathiomolybdate have the synergistic treatment effect. The evidence shows that the tetrathiomolybdate can remarkably improve the chemosensitivity of glioma to temozolomide, meanwhile, the safety is guaranteed, and the tetrathiomolybdate has high clinical application value.

The invention belongs to the technical field of biological medicines, and particularly relates to application of daptomycin in preparation of a non-small cell lung cancer EGFR-TKI drug resistance reversal agent. The invention discloses that daptomycin can effectively reverse drug resistance for the first time: in-vitro experiments show that evaluation is performed by adopting an HSA model of SynergyFinder software, and it is found that the drug combination synergy score of daptomycin and osimertinib in H1975 drug-resistant cells is 18.166, which indicates that daptomycin and osimertinib have a strong synergistic effect, and the drug resistance of daptomycin and osimertinib can be effectively reversed. Cloning formation experiments show that the cell proliferation inhibition rate of a drug combination group is increased by more than 80% compared with that of a single drug group, and a strong synergistic effect is achieved. An in-vivo experiment further verifies that the tumor volume of a combined drug group is reduced by about 80% compared with that of an osimertinib single drug group, the tumor weight is obviously reduced, drug-resistant relapse does not occur in a treatment period of 22 days, and meanwhile, the stability of the weight of a mouse shows that the safety is good. The invention provides a combined treatment scheme with high efficiency and safety for overcoming EGFR-TKI drug resistance, and has important clinical transformation value.

The invention belongs to the field of tumor immunity, discloses application of a pseudomonas alcaligenes composition in preparation of pancreatic cancer treatment drugs, and aims to solve the technical problems that pancreatic cancer immunotherapy is low in response rate and existing treatment schemes are high in toxicity. The pseudomonas alcaligenes used in the invention are sPseudomonas alcaligenes, 4-carboxyphenylacetic acid and 1-(4-carboxybutyl) indole-5-boric acid are used as composite cross-linking agents, the composite cross-linking agents and sodium alginate form a hydrogel carrier, the pseudomonas alcaligenes are efficiently encapsulated, a PD-1 antibody is loaded, the tumor weight of the pancreatic cancer is remarkably reduced, tumor growth is effectively inhibited, and the pancreatic cancer can be effectively inhibited. The triple barriers of pancreatic cancer immunotherapy are successfully broken through; the hydrogel carrier is high in bacterial encapsulation efficiency, can effectively construct a growth microenvironment suitable for pseudomonas alcaligenes and promote bacterial growth, and is excellent in biological safety; and a low-toxicity and high-efficiency brand-new technical scheme is provided for immunotherapy of pancreatic cancer.

The application discloses a kind of attenuated salmonella and amodiaquine combined medicine and application, attenuated salmonella and amodiaquine combined medicine include attenuated salmonella typhimurium VNP20009 and its derivative or genetically modified strain and amodiaquine as active component.Amodiaquine is selectively eliminated neutrophil in tumor microenvironment by targeting binding glutathione reductase in neutrophil and inhibiting its activity.Amodiaquine of the application directly targets glutathione reductase in neutrophil, inhibits its activity, reduces reduced glutathione level, increases active oxygen accumulation, selectively induces neutrophil apoptosis in tumor immune microenvironment, and further enhances the colonization of VNP20009 and its derivative or genetically modified strain in tumor.The combination therapy reduces tumor weight by about 50%, prolongs tumor growth doubling time by 1.5 times, and does not affect the neutrophil level in peripheral blood and important organs, significantly reduces the liver and kidney toxicity of VNP20009 and its derivative or genetically modified strain.

The invention relates to the technical field of biological medicine, in particular to application of vitamin B1 in preparation of a medicine for inhibiting liver cancer. Researches find that the vitamin B1 can significantly inhibit proliferation of hepatoma carcinoma cells and induce death of hepatoma carcinoma cells within a certain dosage range, and presents time and dosage dependence. Furthermore, a liver cancer tumor-bearing animal model verifies that the injection administration of the vitamin B1 can obviously inhibit the increase of the tumor volume and the tumor weight, and the tumor growth tends to be stable under the condition of high dosage. Meanwhile, the vitamin B1 can obviously improve the microcirculation perfusion level of the tumor tissue and improve the blood perfusion amount and the blood cell perfusion speed along with the reduction of the number of tumor tissue capillaries. Animal experiment results show that no obvious toxic or side effect is observed in the administration process of the vitamin B1. The new application of the vitamin B1 in inhibiting the liver cancer is disclosed for the first time, and a new choice with high safety and good potential application value is provided for treatment of the liver cancer.

The invention belongs to the technical field of medicines, and relates to a pharmaceutical composition containing a Chinese knotweed rhizome and aloe bowel-relaxing capsule and used for treating colorectal cancer and application of the pharmaceutical composition. The combination of the Chinese knotweed rhizome and aloe bowel-relaxing capsule and oxaliplatin can significantly improve weight loss of colorectal cancer model mice, reduce the number of tumors and reduce the weight of the tumors, and has a significant synergistic effect in treatment of colorectal cancer. The first-flower knotweed and aloe bowel-relaxing capsule and oxaliplatin are combined to treat colorectal cancer, and meanwhile, the two medicines play a synergistic role, so that the dosage of the medicines is reduced, the toxic and side effects of the medicines are reduced, and the medication safety is improved.

The application relates to application of a combined use of bruceine D and pemetrexed in the preparation of a drug for treating lung cancer, and belongs to the technical field of biological medicine. The combined use of bruceine D (BD) and pemetrexed (PEM) for treating lung cancer shows a synergistic effect, can more effectively inhibit tumor growth than single drugs, more significantly inhibit lung cancer cell activity and proliferation capacity, reduce lung cancer cell colony formation capacity, and inhibit tumor volume increase and terminal tumor weight increase. In a pemetrexed-resistant lung cancer model, the single drug BD can play a significant role in inhibiting tumors, inhibit pemetrexed-resistant lung cancer cell activity, reduce pemetrexed-resistant lung cancer cell colony formation capacity, and show independent anti-tumor activity; it is shown that BD has a significant therapeutic effect on pemetrexed-resistant lung cancer, and provides a new intervention means for pemetrexed-resistant lung cancer.

The invention belongs to the technical field of medicines, and particularly relates to application of Riluzole in preparation of a medicine for treating colon cancer. The invention discloses a drug Riluzole which has very high affinity with GOLGA8B protein, can significantly improve the thermal stability of the GOLGA8B protein and significantly inhibit the growth of colon cancer cells, and the inhibition effect has dose dependence. In addition, the clone formation capability of colon cancer cells can be remarkably inhibited, and the effect of inhibiting the survival of the colon cancer cells is achieved; apoptosis of colon cancer cells can be promoted, and free migration and invasion of the colon cancer cells can be inhibited; the growth of colon cancer tumor (plt; 0.01) can be obviously inhibited, and the tumor volume and the tumor weight are reduced.

The invention relates to an application of a polycyclic polyisopentenyl phloroglucinol compound Atenuamione D, which is extracted and separated from Hypericum sampsonii Hance, in preparation of a medicine for treating hepatocellular carcinoma, in particular to an application of the polycyclic polyisopentenyl phloroglucinol compound Atenuamione D in preparation of a medicine for treating hepatocellular carcinoma. The in-vivo pharmacological research shows that the polycyclic polyisopentenyl phloroglucinol compound can obviously reduce the tumor weight of nude mice with hepatocellular carcinoma under the dosage of 25 mg / kg and 50 mg / kg, can reverse the purine metabolism abnormality of nude mice with hepatocellular carcinoma, and can be used for preparing the medicine for treating hepatocellular carcinoma.

The invention belongs to the field of medicines, and relates to a novel application of a Chinese knotweed rhizome and aloe bowel-relaxing capsule, in particular to a novel application of the Chinese knotweed rhizome and aloe bowel-relaxing capsule in a medicine for treating colorectal cancer. The colorectal cancer model mice are administered with the Chinese knotweed rhizome-aloe bowel-relaxing capsules, the difference of indexes of each group of mice is observed, and the prevention and treatment effect of the Chinese knotweed rhizome-aloe bowel-relaxing capsules on colorectal cancer is investigated. Experimental results show that the Chinese knotweed rhizome and aloe bowel-relaxing capsule not only can obviously improve the body mass of a mouse with colorectal cancer and reduce the number of tumors of the mouse with colorectal cancer, but also can reduce the tumor weight of the mouse with colorectal cancer, and is remarkable in tumor inhibition effect. The Chinese knotweed rhizome and aloe bowel-relaxing capsule is used for treating colorectal cancer, can avoid toxic and side effects of western medicines, and is higher in safety.

The application belongs to the technical field of biological medicine, and particularly relates to a collagen binding domain fusion CCL14 recombinant protein and application thereof. The amino acid sequence of the recombinant protein is shown as SEQ ID NO. 1, and the nucleotide sequence of the encoding gene is shown as SEQ ID NO. 2. The application innovatively applies the chemokine CCL14 to tumor immunotherapy. Compared with the simple CCL14 protein, after the recombinant protein treatment, the tumor weight of the mouse is lighter, and the tumor volume is smaller. Therefore, the collagen binding domain fusion CCL14 recombinant protein is a feasible, innovative and scientific scheme for tumor immunotherapy.

The invention discloses an application of Rupikang capsules in preparation of anti-breast cancer drugs, in-vitro research shows that the Rupikang capsules can significantly inhibit proliferation and migration of human breast cancer cells MDA-MB-231, MDA-MB-468 and BT-549, promote apoptosis of the breast cancer cells and change the morphology of the breast cancer cells, so that the effect of treating breast cancer is achieved; in-vivo research shows that after treatment, the Rupikang capsule can significantly reduce the intensity of bioluminescence signals of mouse breast tumors, reduce the tumor volume and tumor weight of tumor-bearing mice, inhibit growth of the mouse breast tumors and play a role in resisting breast cancer, and the Rupikang capsule has no obvious influence on the weight of the mice and is high in safety. Therefore, the Rupikang capsule has a potential value in the aspect of preparing a medicine for preventing and treating breast cancer or a medicine preparation for inhibiting breast cancer cell proliferation. The Rupikang capsule as a clinical Chinese patent medicine can be directly applied to a human body without clinical safety assessment, and the market share of the product can be rapidly improved.

The invention discloses application of irisin in preparation of a medicine for treating breast cancer. Experimental results show that the tectoridin can effectively delay tumor growth by regulating and controlling the immune system of the body, reduce the weight of the final tumor and prolong the lifetime. In addition, irisin also serves as a muscle factor to remarkably enhance activation and toxicity of the NK cells, and can activate the NK cells in vitro and in vitro. And finally, the PGC-1alpha is proved to be the core transcription factor for regulating LDHB by irisin. In a PGC-1alpha-deficient cell, irisin cannot promote up-regulation of LDHB, and also cannot rescue NK cell disability under an acidification condition. A direct relation is established between an irisin / PGC-1 alpha / LDHB signal channel and the lactic acid tolerance of the NK cells for the first time, and a theoretical basis is provided for a new strategy of tumor immunotherapy based on irisin.

The invention belongs to the technical field of medicines, and particularly relates to application of orientin in preparation of a medicine for treating breast cancer. An MMTV-PyMT breast cancer transgenic mouse is adopted, it is found that the tumor weight inhibition rate of 31.2% is achieved when the PD-L1 monoclonal antibody is independently used, the inhibition rate of orientin single drug treatment is 25.6%, after the PD-L1 monoclonal antibody and the orientin single drug are jointly used, tumor growth can be remarkably inhibited, the tumor inhibition rate reaches 70.0%, and the combined treatment effect is remarkably superior to simple superposition of the drug effects of all the single drugs. In addition, the combined treatment can also effectively promote the infiltration of CD4 + and CD8 + T cells in tumor tissues, and improve the expression level of key anti-tumor immune factors such as granzyme B (GZMB) and interferon-gamma (IFN-gamma).

The invention belongs to the technical field of medicines, discloses application of a compound CA3 in inhibiting leukemia cell proliferation and treating leukemia, and particularly discloses application of the compound CA3 shown as a formula (I) in treating leukemia. Pharmacological experiments prove that the CA3 can obviously inhibit the proliferation of leukemia cells HL-60 (the IC50 value is 5.4 * 10 <-7 > M); the tumor volume of an HL-60 cell ectopic transplantation NOD-SCID mouse is reduced 11 days after the CA3 is administered, and the tumor weight of the HL-60 cell ectopic transplantation NOD-SCID mouse is reduced 14 days after the CA3 is administered. Experimental results show that the CA3 significantly inhibits leukemia cell proliferation at a cellular level and significantly reduces leukemia tumor growth at an animal level.

This invention belongs to the field of pharmaceutical technology and relates to a pharmaceutical composition containing Shouhui Tongbian capsules for the treatment of colorectal cancer and its application. The combination of Shouhui Tongbian capsules and oxaliplatin significantly improves weight loss, reduces tumor number and weight in colorectal cancer model mice, demonstrating a significant synergistic effect in the treatment of colorectal cancer. In this invention, the combination of Shouhui Tongbian capsules and oxaliplatin, while treating colorectal cancer, allows the two drugs to exert a synergistic effect, reducing drug dosage, decreasing drug toxicity and side effects, and improving medication safety.